Opportunity mapping & indication strategy for company developing exosome-based therapies

Challenge: A clinical stage stem-cell company with its own proprietary cell lines had developed technologies to enable production of exosomes at a commercially relevant scale. The company asked...
Learn More

Interim Chief Medical Officer support for an immuno-oncology biopharma company

Challenge: A European biopharma company focused on immuno-oncology therapeutics was developing small molecule and monoclonal antibody agents for three targets of high interest in the I/O field. The...
Learn More

EU payer research for novel mAb treatment for hidradenitis suppurativa

Challenge: A biotech company that had recently completed a late-stage clinical trial for its first-in-class mAb therapy for a chronic inflammatory skin disease wanted to test the use of a newly...
Learn More

Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an...
Learn More

Pre-due diligence of two early-stage assets: a nano-ADC & a small molecule

Challenge: A pharma company sought Alacrita's support in providing high-level go/no-go pre-due diligence of two early-stage strategic investment opportunities. The company had so far been focused on...
Learn More

Strategic analysis of preclinical data for a lipid combination treatment

Challenge: A European biopharma company developing synthetic lipids required a critical appraisal of data generated by a University research group using natural lipids in oncology. It wished to...
Learn More

Pharmaceutical Regulatory Affairs Case Studies

Alacrita's regulatory affairs consultants provide support to biotech, pharmaceutical and medtech clients, as well as companies and investors conducting regulatory due diligence. Our regulatory team...
Learn More

Technical & commercial due diligence of two pipeline cell therapy products

Challenge: Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two...
Learn More

Valuation of viral vector manufacturing spinout

Challenge: A listed biotechnology company had developed a significant capability in viral vector manufacturing and was considering spinning it out into a joint venture with a major CDMO. The client...
Learn More

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...
Learn More

Strategic positioning guidance for Rx microbiome product

Challenge: A company with a microbiome-conditioning product was seeking the optimum strategic positioning to enable a trade sale to a major company. Unusually for a venture in this field, the company...
Learn More

Regulatory strategy and preparation for pre-IND meeting with the FDA

Challenge: A biotech company working in the microbiome space engaged Alacrita to provide advice about regulatory strategy and to prepare for and conduct a pre-IND meeting with the FDA. The product in...
Learn More